A Phase 1 Randomized, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT Administered Intrathoracically in Single and Multiple Doses in Patients With Pleurisy
Latest Information Update: 23 Oct 2024
At a glance
- Drugs OsrhCT (Primary)
- Indications Pleurisy
- Focus Adverse reactions
- Sponsors Wuhan Healthgen Biotechnology
Most Recent Events
- 02 Aug 2024 New trial record